If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
109.50    0.00 (0.00%)
Bid:
107.00
Ask:
112.00
Spread: 5.00 (4.673%)
Market Cap: £14.77m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Joint development agreement with AkzoNobel

27 Jan 2017 11:53

RNS Number : 3527V
Revolymer PLC
27 January 2017
 

27 January 2017

Revolymer plc ("Revolymer")

Joint development agreement with AkzoNobel

Revolymer is pleased to announce that its wholly owned US subsidiary, Itaconix Corporation ("Itaconix"), has signed a joint development agreement with Akzo Nobel Chemicals International B.V. ("AkzoNobel") to advance commercial collaborations in certain applications for the Itaconix itaconic acid polymer technology platform.

The agreement establishes a broad operating framework for the parties to jointly identify, develop and commercialise new polymers using Itaconix's patented technology.

"This innovative technology enables the production of polymers from renewable ingredients, which fits closely with our Planet Possible sustainability agenda of doing more with less," explained Peter Nieuwenhuizen, Research Development & Innovation Director for AkzoNobel's Specialty Chemicals business. "These bio-based polymers offer unique properties in applications essential to our everyday lives, ranging from water quality to cleaning and hygiene."

Dr. Kevin Matthews, CEO of Revolymer, commented: "We share AkzoNobel's commitment to improving the cost and performance of our customers' formulations with increasingly more sustainable products. We are excited to begin working together to identify and develop attractive commercial opportunities for our novel polymers."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley (Corporate Finance)

Nick Owen (Corporate Broking)

 

About Revolymer

Revolymer is an AIM quoted company whose objective is to be a leader in functional polymers that improve the safety, performance or sustainability of its customers' products in the delivery and controlled release of actives, surface modification and water quality improvement for the Homecare & Industrial and Personal Care & Consumer Healthcare markets.

www.revolymer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFDLFLDFFEBBB
Date   Source Headline
10th Jun 20262:43 pmRNSResult of AGM
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.